NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

<p>NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients Based on data generated from its Phase I dose escalation safety trial, presented at the recent CTAD conference in October […]</p>
<p>The post <a href="https://forextv.com/top-news/nkgen-biotech-announces-clearance-of-clinical-trial-application-by-health-canada-for-snk01-nk-cell-therapy-to-treat-alzheimers-disease/">NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>